Biotechnology Value Fund L P insider trades
Biotechnology Value Fund L P has filed 10 Form 4s with the SEC that we hold, for Kymera Therapeutics, Inc. (KYMR) (Director), Olema Pharmaceuticals, Inc. (OLMA) (Director, 10% owner), CTIC (Director, 10% owner) and Cullinan Therapeutics, Inc. (CGEM) (10% owner), among 7 companies in all. Across all of them we count 18 purchases worth $50.0M and 4 sales worth $17.0M reported on Form 4. None of these purchases or sales is dated in the last 12 months. The largest single trade was a purchase of 304,997 shares of Kymera Therapeutics, Inc. worth $14.3M, dated 2021-07-01. The first filing on our record is dated 2021-07-06 and the latest 2025-01-28.
Kymera Therapeutics, Inc. (KYMR)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-07-01 | P, purchase reported on Form 4 | 304,997 | $14.3M | 2021-07-06 |
| 2021-07-01 | P, purchase reported on Form 4 | 211,711 | $10.0M | 2021-07-06 |
| 2021-07-01 | P, purchase reported on Form 4 | 27,458 | $1.3M | 2021-07-06 |
| 2022-05-20 | P, purchase reported on Form 4 | 4,180 | $58.5K | 2022-05-24 |
| 2022-05-20 | P, purchase reported on Form 4 | 37 | $518 | 2022-05-24 |
| 2022-05-20 | P, purchase reported on Form 4 | 5,883 | $82.4K | 2022-05-24 |
Olema Pharmaceuticals, Inc. (OLMA)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-11-30 | P, purchase reported on Form 4 | 362,430 | $3.4M | 2021-12-02 |
| 2021-11-30 | P, purchase reported on Form 4 | 341,977 | $3.2M | 2021-12-02 |
| 2021-11-30 | P, purchase reported on Form 4 | 35,268 | $331.2K | 2021-12-02 |
CTIC
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Cullinan Therapeutics, Inc. (CGEM)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-06-01 | P, purchase reported on Form 4 | 44,746 | $492.2K | 2022-06-03 |
| 2022-06-01 | P, purchase reported on Form 4 | 301,009 | $3.3M | 2022-06-03 |
| 2022-06-01 | P, purchase reported on Form 4 | 405,641 | $4.5M | 2022-06-03 |
RAIN (RAIN)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-07-01 | P, purchase reported on Form 4 | 124,804 | $2.0M | 2021-07-06 |
| 2021-07-01 | P, purchase reported on Form 4 | 172,457 | $2.7M | 2021-07-06 |
| 2021-07-01 | P, purchase reported on Form 4 | 20,018 | $313.3K | 2021-07-06 |
| 2021-07-06 | P, purchase reported on Form 4 | 106,627 | $1.6M | 2021-07-06 |
| 2021-07-06 | P, purchase reported on Form 4 | 146,116 | $2.2M | 2021-07-06 |
| 2021-07-06 | P, purchase reported on Form 4 | 16,980 | $258.9K | 2021-07-06 |
Structure Therapeutics Inc. (GPCR)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
XOMA Royalty Corp (XOMA)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2025-01-24 | S, sale reported on Form 4 | 75,287 | $2.0M | 2025-01-28 |
| 2025-01-24 | S, sale reported on Form 4 | 85,776 | $2.2M | 2025-01-28 |
| 2025-01-24 | S, sale reported on Form 4 | 149,975 | $3.9M | 2025-01-28 |
| 2025-01-24 | S, sale reported on Form 4 | 339,679 | $8.9M | 2025-01-28 |
Counted from the Form 4 filings this reporting owner (SEC CIK 918923) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms